

# Anders Wallin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2158012/publications.pdf>

Version: 2024-02-01

133  
papers

12,484  
citations

47006

47  
h-index

25787

108  
g-index

145  
all docs

145  
docs citations

145  
times ranked

14101  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuropsychological Test Performance Among Native and Non-Native Swedes: Second Language Effects. <i>Archives of Clinical Neuropsychology</i> , 2022, 37, 826-838.	0.5	14
2	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	9.0	97
3	Blood-brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein <sup>12</sup> in patients with subcortical small-vessel disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12296.	2.4	5
4	Shared CSF Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus and Subcortical Small Vessel Disease. <i>Frontiers in Neurology</i> , 2022, 13, 839307.	2.4	8
5	Higher thyroid function is associated with accelerated hippocampal volume loss in Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2022, 139, 105710.	2.7	4
6	Testosterone associates differently with body mass index and age in serum and cerebrospinal fluid in men. <i>Journal of Internal Medicine</i> , 2022, 292, 684-686.	6.0	3
7	Low Serum Insulin-like Growth Factor-I Is Associated with Decline in Hippocampal Volume in Stable Mild Cognitive Impairment but not in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1007-1016.	2.6	1
8	Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 729-741.	2.6	10
9	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464.	0.8	13
10	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 712545.	3.4	16
11	Cerebrospinal Fluid Sulfatide Levels Lack Diagnostic Utility in the Subcortical Small Vessel Type of Dementia. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 781-790.	2.6	3
12	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. <i>Biomedicines</i> , 2021, 9, 1610.	3.2	7
13	Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline. <i>Stroke</i> , 2020, 51, 170-178.	2.0	115
14	The five-item memory screen extended variant: A tool for assessing memory. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 162-167.	2.1	0
15	Characteristic Biomarker and Cognitive Profile in Incipient Mixed Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 597-607.	2.6	8
16	Latent Cognitive Profiles Differ Between Incipient Alzheimer's Disease and Dementia with Subcortical Vascular Lesions in a Memory Clinic Population. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 955-966.	2.6	1
17	Altered thyroid hormone profile in patients with Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2020, 121, 104844.	2.7	21
18	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020, 10, 403.	4.8	42

#	ARTICLE	IF	CITATIONS
19	Demographically adjusted trail making test norms in a Scandinavian sample from 41 to 84 years. <i>Clinical Neuropsychologist</i> , 2020, 34, 110-126.	2.3	15
20	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	2.6	7
21	Regression-based normative data for the Rey Auditory Verbal Learning Test in Norwegian and Swedish adults ages 40 to 80. <i>Alzheimer's and Dementia</i> , 2020, 16, e044431.	0.8	0
22	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225.	2.6	13
23	Patients with Alzheimer's Disease Have Increased Levels of Insulin-like Growth Factor-I in Serum but not in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 289-298.	2.6	10
24	The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial. <i>Frontiers in Neurology</i> , 2020, 11, 149.	2.4	14
25	Patients with the Subcortical Small Vessel Type of Dementia Have Disturbed Cardiometabolic Risk Profile. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1373-1383.	2.6	2
26	Predictive and diagnostic utility of brief neuropsychological assessment in detecting Alzheimer's pathology and progression to dementia.. <i>Neuropsychology</i> , 2020, 34, 851-861.	1.3	5
27	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.	0.8	46
28	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	9.0	455
29	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827.	0.8	62
30	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019, 15, 776-787.	0.8	134
31	White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 107-117.	3.7	250
32	Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer's disease patients. <i>Scientific Reports</i> , 2019, 9, 5522.	3.3	20
33	A metabolite-based machine learning approach to diagnose Alzheimer's type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938.	3.7	70
34	Device-Measured Sedentary Behavior, Physical Activity and Aerobic Fitness Are Independent Correlates of Cognitive Performance in Healthy Middle-Aged Adults—Results from the SCAPIS Pilot Study. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 5136.	2.6	11
35	Low serum concentration of free triiodothyronine (FT3) is associated with increased risk of Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2019, 99, 112-119.	2.7	33
36	Vascular dysfunction—The disregarded partner of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 158-167.	0.8	454

#	ARTICLE	IF	CITATIONS
37	Delineation of two intracranial areas and the perpendicular intracranial width is sufficient for intracranial volume estimation. <i>Insights Into Imaging</i> , 2018, 9, 25-34.	3.4	4
38	Update on Vascular Cognitive Impairment Associated with Subcortical Small-Vessel Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1417-1441.	2.6	90
39	Cognitive medicine – a new approach in health care science. <i>BMC Psychiatry</i> , 2018, 18, 42.	2.6	15
40	Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\beta$ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
41	Similar pattern of atrophy in early- and late-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 253-259.	2.4	16
42	Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. <i>Biological Psychiatry</i> , 2018, 83, 447-455.	1.3	83
43	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. <i>Alzheimer's and Dementia</i> , 2018, 14, 280-292.	0.8	246
44	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
45	P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1161.	0.8	0
46	Estimated intracranial volume from FreeSurfer is biased by total brain volume. <i>European Radiology Experimental</i> , 2018, 2, .	3.4	25
47	F1-02-02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION. <i>Alzheimer's and Dementia</i> , 2018, 14, P201.	0.8	0
48	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 100.	6.2	64
49	P2-458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P895.	0.8	0
50	F1-02-03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P202.	0.8	0
51	Better prognostic accuracy in younger mild cognitive impairment patients with more years of education. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 402-412.	2.4	6
52	Amyloid- $\beta$ , Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 193.	3.4	16
53	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 64.	6.2	62
54	Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 96-107.	2.4	29

#	ARTICLE	IF	CITATIONS
55	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	2.4	197
56	Differences in the use of everyday technology among persons with MCI, SCI and older adults without known cognitive impairment. <i>International Psychogeriatrics</i> , 2017, 29, 1193-1200.	1.0	19
57	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	3.1	27
58	Imaging biomarkers of dementia: recommended visual rating scales with teaching cases. <i>Insights Into Imaging</i> , 2017, 8, 79-90.	3.4	67
59	The Vascular Impairment of Cognition Classification Consensus Study. <i>Alzheimer's and Dementia</i> , 2017, 13, 624-633.	0.8	143
60	Low serum insulin-like growth factor-I (IGF-I) level is associated with increased risk of vascular dementia. <i>Psychoneuroendocrinology</i> , 2017, 86, 169-175.	2.7	20
61	Working memory and attention are still impaired after three years in patients with stress-related exhaustion. <i>Scandinavian Journal of Psychology</i> , 2017, 58, 504-509.	1.5	35
62	Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1017-1026.	2.6	24
63	Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report. <i>BMC Neurology</i> , 2017, 17, 102.	1.8	65
64	[P1-289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF A $\beta$ 2 OR AMYLOID-PET) IN THE EMIF-AD BIOMARKER DISCOVERY COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P361.	0.8	0
65	[P2-212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER'S DISEASE (EMIF-AD): THE BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P691.	0.8	1
66	Subjective Cognitive Impairment Is a Predominantly Benign Condition in Memory Clinic Patients Followed for 6 Years: The Gothenburg-Oslo MCI Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017, 7, 1-14.	1.3	51
67	Preclinical effects of APOE $\epsilon$ 4 on cerebrospinal fluid A $\beta$ 242 concentrations. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 87.	6.2	22
68	Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment. <i>PLoS ONE</i> , 2017, 12, e0176760.	2.5	18
69	A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1353-1363.	2.6	28
70	Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016, 6, 283-294.	1.3	33
71	Boston Naming Test automatic credits inflate scores of nonaphasic mild dementia patients. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 381-392.	1.3	7
72	The Gothenburg MCI study: Design and distribution of Alzheimer's disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 114-131.	4.3	67

#	ARTICLE	IF	CITATIONS
73	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.	0.8	179
74	Alzheimer's disease's subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 95-113.	4.3	42
75	Consensus statement for diagnosis of subcortical small vessel disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 6-25.	4.3	173
76	Differential Impact of Neurofilament Light Subunit on Cognition and Functional Outcome in Memory Clinic Patients with and without Vascular Burden. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 873-881.	2.6	12
77	Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 637-646.	2.6	40
78	First Administration of the Fc-Attenuated Anti- $\beta$ 2 Amyloid Antibody GSK933776 to Patients with Mild Alzheimer's Disease: A Randomized, Placebo-Controlled Study. <i>PLoS ONE</i> , 2015, 10, e0098153.	2.5	27
79	Multimodal Prediction of Dementia with up to 10 Years Follow Up: The Gothenburg MCI Study. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 205-214.	2.6	40
80	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015, 138, 1327-1338.	7.6	284
81	Valid and efficient manual estimates of intracranial volume from magnetic resonance images. <i>BMC Medical Imaging</i> , 2015, 15, 5.	2.7	9
82	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	7.4	1,166
83	Frequent Mild Cognitive Deficits in Several Functional Domains in Elderly Patients With Heart Failure Without Known Cognitive Disorders. <i>Journal of Cardiac Failure</i> , 2015, 21, 702-707.	1.7	20
84	Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 2015, 609, 58-62.	2.1	20
85	Shape Abnormalities of the Caudate Nucleus Correlate with Poorer Gait and Balance: Results from a Subset of the LADIS Study. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 59-71.e1.	1.2	16
86	Physical activity in the elderly is associated with improved executive function and processing speed: the LADIS Study. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 744-750.	2.7	51
87	Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 385-394.	1.3	33
88	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. <i>JAMA Psychiatry</i> , 2014, 71, 1183.	11.0	85
89	Cardiovascular and cognitive fitness at age 18 and risk of early-onset dementia. <i>Brain</i> , 2014, 137, 1514-1523.	7.6	97
90	The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014, 10, 713.	0.8	249

#	ARTICLE	IF	CITATIONS
91	Neuronal and Glia-Related Biomarkers in Cerebrospinal Fluid of Patients with Acute Ischemic Stroke. <i>Journal of Central Nervous System Disease</i> , 2014, 6, JCNSD.S13821.	1.9	82
92	The Combination of Dysexecutive and Amnesic Deficits Strongly Predicts Conversion to Dementia in Young Mild Cognitive Impairment Patients: A Report from the Gothenburg-Oslo MCI Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 76-85.	1.3	14
93	P4-063: APOE GENOTYPE AND CSF A $\beta$ 42 IN COGNITIVELY HEALTHY INDIVIDUALS. , 2014, 10, P806-P806.		0
94	Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2013, 38, 1058-1066.	2.7	38
95	White Matter Lesion Assessment in Patients with Cognitive Impairment and Healthy Controls: Reliability Comparisons between Visual Rating, a Manual, and an Automatic Volumetric MRI Methodâ€”The Gothenburg MCI Study. <i>Journal of Aging Research</i> , 2013, 2013, 1-10.	0.9	31
96	Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e81989.	2.5	45
97	Low Cerebrospinal Fluid Sulfatide Predicts Progression of White Matter Lesions â€” The LADIS Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 61-67.	1.5	19
98	Characteristic clinical presentation and CSF biomarker pattern in cerebral small vessel disease. <i>Journal of the Neurological Sciences</i> , 2012, 322, 192-196.	0.6	25
99	Monte Carlo feature selection and rule-based models to predict Alzheimerâ€™s disease in mild cognitive impairment. <i>Journal of Neural Transmission</i> , 2012, 119, 821-831.	2.8	13
100	Cerebrospinal Fluid Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Combination with Subcortical and Cortical Biomarkers in Vascular Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 665-676.	2.6	150
101	Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimerâ€™s Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2011, 1, 31-42.	1.3	35
102	Biomarkers in vascular dementia. , 2009, , 77-92.		1
103	Subcortical Vascular Dementia Biomarker Pattern in Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 348-356.	1.5	45
104	Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. <i>BMJ: British Medical Journal</i> , 2009, 339, b2477-b2477.	2.3	348
105	Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2009, 30, 682-690.	3.1	174
106	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 385.	7.4	1,009
107	B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia. <i>NeuroReport</i> , 2009, 20, 825-827.	1.2	28
108	Risk of Rapid Global Functional Decline in Elderly Patients With Severe Cerebral Age-Related White Matter Changes. <i>Archives of Internal Medicine</i> , 2007, 167, 81.	3.8	187



#	ARTICLE	IF	CITATIONS
109	White matter changes and late-life depressive symptoms. <i>British Journal of Psychiatry</i> , 2007, 191, 212-217.	2.8	141
110	Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years. <i>Journal of Alzheimer's Disease</i> , 2007, 12, 255-260.	2.6	117
111	National Institute of Neurological Disorders and Strokeâ€œCanadian Stroke Network Vascular Cognitive Impairment Harmonization Standards. <i>Stroke</i> , 2006, 37, 2220-2241.	2.0	1,445
112	Classification and Subtypes of Vascular Dementia. <i>International Psychogeriatrics</i> , 2003, 15, 27-37.	1.0	39
113	Decreased Cerebrospinal Fluid Acetylcholinesterase in Patients with Subcortical Ischemic Vascular Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 200-207.	1.5	41
114	Subcortical ischaemic vascular dementia. <i>Lancet Neurology</i> , The, 2002, 1, 426-436.	10.2	958
115	Pathophysiological aspects of frontotemporal dementiaâ€œemphasis on cytoskeleton proteins and autoimmunity. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 1923-1935.	4.6	24
116	Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 1937-1949.	4.6	51
117	Frontotemporal Dementia Can Be Distinguished from Alzheimerâ€™s Disease and Subcortical White Matter Dementia by an Anterior-to-Posterior rCBF-SPET Ratio. <i>Dementia and Geriatric Cognitive Disorders</i> , 2000, 11, 275-285.	1.5	60
118	Limitations of Clinical Criteria for the Diagnosis of Vascular Dementia in Clinical Trials: Is a Focus on Subcortical Vascular Dementia a Solution?. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 262-272.	3.8	100
119	Subcortical Vascular Dementia as a Specific Target for Clinical Trials. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 510-521.	3.8	36
120	Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. <i>Journal of the Neurological Sciences</i> , 2000, 175, 124-134.	0.6	89
121	Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. <i>Journal of Clinical Immunology</i> , 1999, 19, 223-230.	3.8	300
122	White Matter Changes on CT and MRI: An Overview of Visual Rating Scales. <i>European Neurology</i> , 1998, 39, 80-89.	1.4	244
123	SYMPTOMATOLOGICAL CHARACTERISTICS DISTINGUISH BETWEEN FRONTOTEMPORAL DEMENTIA AND VASCULAR DEMENTIA WITH A DOMINANT FRONTAL LOBE SYNDROME. <i>International Journal of Geriatric Psychiatry</i> , 1997, 12, 656-661.	2.7	40
124	SYMPTOMATOLOGICAL CHARACTERISTICS DISTINGUISH BETWEEN FRONTOTEMPORAL DEMENTIA AND VASCULAR DEMENTIA WITH A DOMINANT FRONTAL LOBE SYNDROME. <i>International Journal of Geriatric Psychiatry</i> , 1997, 12, 656-661.	2.7	3
125	Decreased Lumbar Cerebrospinal Fluid Levels of Monoamine Metabolites in Vascular Dementia. <i>International Psychogeriatrics</i> , 1996, 8, 425-436.	1.0	21
126	Stepwise Comparative Status Analysis (STEP): A Tool for Identification of Regional Brain Syndromes in Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1996, 9, 185-199.	2.3	84



#	ARTICLE	IF	CITATIONS
127	Ubiquitin in Cerebrospinal Fluid in Alzheimer's Disease and Vascular Dementia. International Psychogeriatrics, 1994, 6, 13-22.	1.0	37
128	Heterogeneity of Vascular Dementia: Mechanisms and Subgroups. Journal of Geriatric Psychiatry and Neurology, 1993, 6, 177-188.	2.3	51
129	Protein Analyses in Cerebrospinal Fluid. European Neurology, 1993, 33, 126-128.	1.4	80
130	Clinical diagnosis of Alzheimer's disease by primary care physicians and specialists. Acta Neurologica Scandinavica, 1992, 85, 26-31.	2.1	5
131	Subcortical symptoms predominate in vascular dementia. International Journal of Geriatric Psychiatry, 1991, 6, 137-145.	2.7	39
132	Presence of parieto-temporal symptomatology distinguishes early and late onset Alzheimer's disease. International Journal of Geriatric Psychiatry, 1991, 6, 147-154.	2.7	47
133	Cerebral small vessel disease: cerebrospinal fluid aspects. , 0, , 200-216.		0